Skip to content

ESBL in Patients Returning to Sweden With Traveller's Diarrhoea

ESBL-producing Enterobacteriaceae in Patients With Traveller's Diarrhoea- a Prospective Cohort Study.

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03866291
Enrollment
305
Registered
2019-03-07
Start date
2017-02-01
Completion date
2019-06-20
Last updated
2019-07-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Antibiotic Resistant Infection, Antibiotic Resistant Strain, Traveler's Diarrhea

Brief summary

Patients with traveller's diarrhoea frequently harbour Extended Spectrum Betalactamase (ESBL)-producing Enterobacteriaceae (EPE) returning from EPE-endemic areas. This study investigates to what extent travellers returning to Sweden with traveller's diarrhoea carry ESBL in their stool. The isolates are examined further according to species, phenotype, antibiogram and whole genome sequencing.

Detailed description

Samples sent to the department of clinical microbiology in Lund, Sweden for culture of salmonella, shigella, yersinia or campylobacter are also cultured selectively for ESBL. All patients are contacted by mail with the results. ESBL-positive patients are invited to submit further faecal cultures and blood samples during one year follow up time, to investigate how long the patient is colonized with ESBL.

Interventions

Sponsors

Lund University
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL

Inclusion criteria

* Travellers diarrhoea * foreign traveller

Exclusion criteria

* foreign traveller but no symptoms

Design outcomes

Primary

MeasureTime frameDescription
Proportion ESBL-colonized after one year.1 yearDefined as a Positive ESBL-culture obtained 12 months after travel

Countries

Sweden

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 25, 2026